Código QR (código de barras bidimensional)

Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review

Epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon <i>EGFR</i> mutations show variable responses, and resistance often develops. The C797S mutation is a commo...

ver descrição completa

Na minha lista:
Principais autores: Wenting Lu, Jiayi Sun, Yawan Jing, Jing Xu, Chengming Huang, Yi Deng, Panwen Tian, Yalun Li
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2025-03-01
coleção:Current Oncology
Assuntos:
NSCLC
<i>EGFR</i> mutation
<i>EGFR</i>-TKI
osimertinib
gefitinib
bevacizumab
Acesso em linha:https://www.mdpi.com/1718-7729/32/4/201
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados